Trial Profile
A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Seladelpar (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Therapeutic Use
- Sponsors CymaBay Therapeutics
- 14 Apr 2018 Results assessing the mechanism of action of Seladelpar in PBC and NASH patients from phase II studies (NCT00701883, NCT02472535, NCT02609048 and NCT02955602) presented at The International Liver Congress 2018
- 11 May 2016 Results will be presented at the 84th European Atherosclerosis Society (EAS) Congress 2016, according to a CymaBay media release.
- 17 Mar 2016 Top-line results were published in a CymaBay Therapeutics media release.